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Increasing the Pool of Academically Oriented
African-American Medical and Surgical
Oncologists
The commendable article by Newman et al.,1 “Increasing the Poolof Academically Oriented African-American Medical and Surgical
Oncologists,” highlights an issue worthy of serious consideration. Not
only must more effort be expended to raise the interest of African
American medical students and physicians in academic oncology, but
the disproportionately low representation of African Americans in
medical school also must be recognized as a partly (if not wholly)
systemic failure worthy of corrective attention. The oncology com-
munity should take an objective look at the factors that gave rise to
and continue to perpetuate an unrepresentative oncology workforce
excluding African Americans. This state of affairs arose historically on
the basis of unabashed white privilege justified by illusions of insep-
arable racial superiority and inferiority. The beneficiaries of such
apartheid-scale privilege are understandably loath to know the mag-
nitude to which their sometimes stellar achievements stand dimin-
ished by such contextual foundations of cultural insensitivity and
exclusion. Even while notable contemporary academic oncologists
condemn the cancer disparities that affect the populations they treat,
there is insufficient general recognition of the disparity among too
many academic oncologists who were largely self-appointed to the
near exclusive privilege of managing the social and institutional re-
sources mandated to research solutions. Scarcely 1% of American
medical oncologists are African American. Undoubtedly, this is the
case in other oncology subspecialties as well. These figures are best
approximations, because no thorough demographic study of the on-
cology workforce has been published. Our preeminent cancer spe-
cialty society, the American Society of Clinical Oncology,2 described
its membership in 2000 as including over 11,000 medical oncologists,
with only 94 who described themselves as African American. In aca-
demic oncology, surrogate indicators of ‘race’ appear to have sup-
planted overt racism, preserving deterrents to representative inclu-
sion of African Americans in faculty positions with ‘color-blind’
precision. Because networks of these faculty members influence on-
cologist staffing in metropolitan community hospitals, the basis for
market exclusion of African American cancer specialists is established
in communities where African Americans live in large numbers. A
superficial validation for this state of affairs may suggest that I am
criticizing a rigorously sound meritocracy. The failing of such a con-
clusion lies in the prevalence of disparities in cancer mortality among
the populations being treated by mostly commendable healers who
have altruistic intentions with socially evolved boundaries to requisite
cultural experiences. I have labored to believe that a better job would
be done by all of us working together with curative intentions in
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addressing all of the disparities that constitute soci-
ety’s cancer burden.
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We appreciate Dr. Taylor’s concerns, in response toour previous article,1 that the lack of ethnic di-
versity within the medical oncology community, and
in particular the notable deficit in African American
oncologists, has contributed to the ethnicity-related
cancer outcome disparities that have been observed in
the United States. It is appropriate for this issue to
receive increased scrutiny at this time, when the le-
gality of affirmative action is once again facing judicial
challenge. As a medical oncology community, we
must either be willing to accept our own limited eth-
nic heterogeneity and the resulting potential for in-
creased difficulty in delivering optimal care to an eth-
nically diverse patient population, or we must be
proactive in strengthening the diversity of our own
ethnic composition. The demographics of the Ameri-
can population are shifting in the direction of larger
minority-ethnicity communities. These trends cannot
be influenced by the medical community (nor would
we want them to be); however, we can exert some
measure of control over the extent to which the mem-
bers of the medical community reflect this diversity.
Patient compliance and implementation of clinical
trials are completely dependent on patient trust. If we
accept the concept that our patients are likely to more
readily trust a health care community that reflects
their own diversity in culture, values, and ethnicity,
then it is imperative that we aggressively address and
correct any deficiencies in these areas. This can be
accomplished with energetic mentorship and recruit-
ment efforts.
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Mediastinal Irradiation in Patients
with Esophageal Carcinoma after
Heart Transplantation
In this correspondence, we report our experienceusing mediastinal irradiation in the treatment of a
patient with esophageal carcinoma 8 years after heart
transplantation. The number of heart transplantations
performed appears to increase every year. The survival
of these patients is reportedly improved with the use
of cyclosporins for immunosuppression.1 Some of
these patients are long-term survivors and the risk of
treating them in oncology departments increases in
time. As many as 30% of patients who undergo organ
transplantation develop precancerous lesions and ma-
lignant tumors.2 If the cancer requires a radiation
target-volume involving parts of a transplanted heart,
a number of questions arise for the radiation oncolo-
gist.3 The tolerance of the heart for radiation has been
studied previously,4,5 but to our knowledge no suffi-
cient data have been collected to date.3
A male patient age 52 years who had a history of
chronic tobacco use and alcohol intoxication pre-
sented to the study institution. The patient had un-
dergone a heart transplantation in 1993 for end-stage
ischemic cardiomyopathy with left ventricle severe
dysfunction. After the transplantation, the patient was
treated with cyclosporin, azathioprin, and corticoids.
In January 2002, the patient presented with dys-
phagia, weight loss, and impaired performance status
(PS)2. Fibroscopy demonstrated stenosis and a large
tumor (measuring 40 mm  30 mm  25 mm) situated
within 30 cm of the dental arch. Biopsy was performed
and demonstrated squamous cell carcinoma. There
were no peritumoral lymph nodes detected on the
Correspondence 2737
computed tomography (CT) scan, but some mediasti-
nal lymph nodes were found. There were no distant
metastases. After discussion between physicians in
multiple disciplines, Santy-Lewis surgery was per-
formed. Finally, the tumor was classified as pT3pN2R1
(according to the TNM Staging System). There were 20
positive lymph nodes found. After a second multidis-
ciplinary discussion, postoperative radiotherapy was
proposed. Conformal radiotherapy was performed us-
ing an 18-megavolt (MV) accelerator. A total dose of 45
grays (Gy) in 25 fractions was delivered to the refer-
ence point. Because of the higher risk to the trans-
planted heart, the cardiac structures were delineated
in all CT slides. The heart received a median dose of
8.6 Gy (range, 0.34 – 43.6 Gy). Approximately 85% of
the cardiac volume received  25 Gy. A strict program
of cardiac examinations (comprised of electrocardio-
gram, cardiac ultrasound, ejection fraction, standard
blood tests, and cardiac enzymes) before, during, and
after radiotherapy was established. The radiotherapy
was well tolerated with Radiation Treatment Oncology
Group (RTOG) Grade 2 dysphagia reported without
any cardiac symptoms. A full cardiac examination was
performed at 1 month, 3 months, and 6 months after
irradiation and demonstrated no changes compared
with pretreatment examinations (the left ventricular
ejection fraction was 63%, and all cardiac enzymes
were normal). Complete remission of the esophageal
carcinoma was obtained. One month after last follow-
up (7 months after radiotherapy), the patient died (by
suicide).
Mediastinal irradiation after heart transplantation
is feasible and should be considered after evaluation
of the risk. Conformal radiotherapy or intensity-mod-
ulated radiotherapy appears to be the most appropri-
ate treatment.
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Hospitalization of an Oncology
Patient Suspected of Having Severe
Acute Respiratory Syndrome
A Setup for an Infection Control
Quagmire at a Comprehensive
Cancer Center
Severe acute respiratory syndrome (SARS), causedby the SARS coronavirus, has emerged as a grave
public health concern worldwide.1 Due to the poten-
tial for nosocomial transmission to patients2 and
healthcare workers (HCWs)3 and the ability of SARS to
lead to progressive and potentially fatal pneumonia
without known effective therapy,4 especially in high-
risk individuals,5 infection containment strategies are
of the utmost importance. Recently, a patient sus-
pected of having SARS required hospitalization at our
tertiary cancer center (M. D. Anderson Cancer Center,
Houston, TX).
A 48-year-old male with Hodgkin disease in clin-
ical remission presented with 1 day of fever (39.0 °C),
nonproductive cough, nasal congestion, headache,
and photophobia. His symptoms commenced while
he was returning from a trip to Bangkok, Thailand;
Kuala Lumpur, Malaysia; and Singapore in June 2003.
He appeared acutely ill and had a white blood cell
count of 4000 cells/L (lymphocyte count, 960 cells/
L), and a chest radiograph showed interstitial infil-
trates in the right lower lobe. Respiratory (nasopha-
ryngeal [NP]) samples were evaluated for influenza A
and B, parainfluenza, respiratory syncytial virus, hu-
man cytomegalovirus, and SARS coronavirus. Moxi-
floxacin (400 mg) and trimethoprim-sulfamethoxazole
(15 mg/kg) were administered empirically.
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On the patient’s arrival to the emergency center
(EC), he promptly was secured in a negative air pres-
sure (NAP) room. A security guard supervised strict
compliance to 1) a patient contact log; 2) airborne
precautions (N-95 mask); and 3) contact precautions
(double gloves, double gowns, and disposable eye
shields). The outer contact layers were disposed of
inside the room; the inner layers and eye shields were
discarded immediately outside the room. A single
nurse was assigned, and the patient was admitted to
the NAP room with a ventilation system that was sep-
arate from units that housed patients with hemato-
logic malignancies and hematopoietic stem cell trans-
plant recipients. Before further use, the EC room first
was decontaminated thoroughly with 10% bleach so-
lution and then decontaminated again 12 hours later.
The patient’s spouse visited daily and had restricted
institutional access (between the patient’s room and
the parking garage, with the spouse wearing an N-95
mask). All patient-contact HCWs were retested for
N-95 mask seal adequacy. Pulmonary consultation
was obtained; portable mechanical ventilation and
cardiovascular monitoring units were secured. The
primary oncologist provided non-patient-contact
guidance. Influenza A antigen was detected in NP
samples, and treatment with amantadine (100 mg)
plus oseltamivir (75 mg) was initiated. Nonetheless,
due to concerns regarding concomitant infection,5 in-
fection containment measures remained uninter-
rupted. SARS coronavirus cultures and serology assays
yielded negative results; the presence of influenza A
serotype H3N2 was confirmed. The patient was dis-
charged 72 hours after admission.
Due to uncertain infectious inoculum and poten-
tial airborne routes of person-to-person transmis-
sion,5,6 devising effective infection containment strat-
egies is a daunting task, especially at institutions with
prominent high-risk populations. The cautious infec-
tion containment approach presented includes 1) des-
ignated hospital units with secured ventilation sys-
tems; 2) restricted institutional access for patients,
family members, and HCWs with prolonged patient
exposure; 3) identification of primary and backup
teams, including infection control personnel, infec-
tious disease, and pulmonary and critical care physi-
cians and nurses; and 4) continuation of infection
control measures until the results of specific SARS
coronavirus diagnostic tests become available. These
measures may serve as an outline for preventing the
potentially devastating nosocomial spread of SARS in
centers that provide care for high-risk patients.
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